Sector News

BioMarin snaps up Prosensa for around $840m

November 24, 2014
Life sciences
BioMarin Pharmaceuticals is acquiring Dutch group Prosensa in a deal valued at up to around $840 million.
 
The group said it will offer to buy all of Prosensa’s outstanding ordinary stock for $17.75 per share, for a total upfront consideration of around $680 million, as well as two $80-million milestones contingent on the approval of drisapersen for Duchenne Muscular Dystrophy (DMD) in the US (no later than May 15, 2016) and Europe (before February 15, 2017).
 
The move buys BioMarin access to multiple orphan-drug candidates – such as drisapersen, which has a shot at becoming first approved treatment for the rare genetic disease, albeit for about just 13% of patients (who carry a particular mutation) – leveraging the firm’s proprietary RNA-modulating technology platform for the treatment of various genotypes of DMD and other genetic disorders.      
 
The transaction is expected to be accounted for as a business combination, BioMarin said, also noting that it plans to maintain operations at Prosensa’s headquarters, based in Leiden, The Netherlands and integrate personnel from that office. 
 
“BioMarin is dedicated to the rare disease community, and the acquisition of Prosensa fits strategically with our mission of delivering therapies that address serious unmet medical needs,” said its chief Jean-Jacques Bienaimé, while Prosensa’s head said the move while help his firm’s mission by “bringing innovative therapies to patients across the world as quickly and efficiently as possible”.
 
By Selina McKee
 
Source: Pharma Times

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”